Clinical trials: Ulcerative Colitis
Ulcerative Colitis
Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects
This study evaluates the safety and tolerability of TOP1288 rectal single and multiple ascending doses in healthy subjects and multiple doses in subjects with ulcerative colitis.
- Trial name
- NCT02463045
- Testing
- TOP1288
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Topivert Pharma Ltd
Ulcerative Colitis
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response…
- Trial name
- NCT02426372
- Testing
- QBECO SSI
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Qu Biologics Inc.
Ulcerative Colitis
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.
- Trial name
- NCT04882683
- Testing
- Prednisone, Azathioprine, Adalimumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Psoriasis, Ulcerative Colitis
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Phase 1 study in 2 stages with 2 expansion cohorts. The first stage is a single ascending dose (SAD) study of APVO210 in healthy volunteers.
- Trial name
- NCT03768219
- Testing
- APVO210
- Where
- Australia
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Aptevo Therapeutics
Ulcerative Colitis
Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00767728
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and…
- Trial name
- SELECTION (NCT02914522)
- Testing
- Filgotinib, PTM filgotinib
- Where
- 343 sites in United States, Argentina and 38 more
- Volunteers
- 1,351 people
- Sponsor
- Gilead Sciences
Colitis, Ulcerative
Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.
This is an open label exploratory study to investigate the safety of 400 milligram (mg ) twice a day (b.i.d.) GSK2586184 in patients with moderate to severe, active ulcerative colitis (UC).
- Trial name
- NCT02000453
- Testing
- GSK2586184 400mg
- Where
- Netherlands
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis (UC)
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT02065622
- Testing
- Adalimumab
- Where
- 173 sites in United States, Austria and 18 more
- Volunteers
- 952 people
- Sponsor
- AbbVie
Inflammatory Bowel Diseases
Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) is a prevalent condition, comprising two major types: (1) Crohn disease (chronic enteritis characterized by abdominal pain, stool irregularities, fatigue, weight loss, and malnutrition) and (2)…
- Trial name
- NCT06637683
- Testing
- LiveSpo COLON, Routine treatment
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Anabio R&D
Colitis, Ulcerative, Crohn Disease
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group.
- Trial name
- NCT07483073
- Testing
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
- Where
- 70 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis
This is a Phase 2, multi center, randomized, placebo controlled parallel group study to evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to severely active ulcerative colitis
- Trial name
- NCT04096573
- Testing
- LC51-0255
- Sponsor
- LG Chem
Ulcerative Colitis
This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.
The aim of this study is to describe and evaluate clinical outcomes, treatment lines, and to identify the key characteristics of the patients treated with tofacitinib.
- Trial name
- NCT05082428
- Where
- Finland
- Volunteers
- 252 people
- Sponsor
- Pfizer
Colitis, Ulcerative
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative…
- Trial name
- NCT07768254
- Testing
- Biological: HX15001
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Crohn's Disease, Ileitis
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.
- Conditions
- Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Disease, Granulomatous Colitis
- Trial name
- TOSCA (NCT01387594)
- Testing
- lumbar puncture
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Shire
Ulcerative Colitis
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to…
- Trial name
- NCT03518086
- Testing
- Mirikizumab
- Where
- 502 sites in United States, Argentina and 33 more
- Volunteers
- 1,281 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis (UC)
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis
A study to investigate the safety, tolerability, and pharmacokinetics (PK) of ONO-6414 orally in healthy adult participants and in patients with active ulcerative colitis (UC).
- Trial name
- NCT07749768
- Testing
- ONO-6414
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Ulcerative Colitis, Crohn's Disease
Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract.
- Trial name
- NCT06459297
- Where
- 14 sites in South Korea
- Volunteers
- 105 people
- Sponsor
- AbbVie
Colitis, Ulcerative
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources.
- Trial name
- NCT01240915
- Testing
- MultiStem low dose, MultiStem high dose
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Crohn Disease, Ulcerative Colitis
The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
A multi-center observational study based at referral centers and community hospitals within the US. Patients' blood will be collected at enrollment for testing with PredictSURE IBD™, which will occur at a later date.
- Conditions
- Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
- Trial name
- NCT03952364
- Testing
- PredictSURE IBD™
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- PredictImmune Ltd
Ulcerative Colitis
Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
This is an open label, single-arm, proof of mechanism study to explore the efficacy and safety of rectally administered BBT-401-1S in subjects with ulcerative colitis.
- Trial name
- NCT04478825
- Testing
- BBT-401-1S
- Where
- 2 sites in New Zealand
- Volunteers
- 2 people
- Sponsor
- Bridge Biotherapeutics, Inc.